EUCTR2017-004901-41-FI进行中（未招募）1 期
A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective Coronary Artery Bypass Grafting - PREFER-CABG
Hospital District of Southwestern Finland0 个研究点目标入组 220 人开始时间: 2018年4月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients undergoing non-urgent and non-emergent coronary artery bypass grafting surgery.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •Iron transport and iron storage parameters above normal population values and iron or hemoglobin metabolism disorders (e.g. hemochromatosis, thalassemia).
- •Need for urgent or emergent coronary surgery.
- •Concomitant surgery other than coronary artery surgery planned.
研究者
相似试验
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmPrevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm.MedDRA version: 20.0 Level: LLT Classification code 10028154 Term: Multi-organ failure System Organ Class: 100000004867EUCTR2014-000899-25-GBFaron Pharmaceuticals Ltd152
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmPrevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm.MedDRA version: 20.0 Level: LLT Classification code 10036654 Term: Prevention System Organ Class: 100000022817MedDRA version: 20.0 Level: PT Classification code 10002885 Term: Aortic aneurysm repair System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0 Level: PT Classification code 10002886 Term: Aortic aneurysm rupture System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: LLT Classification code 10028154 Term: Multi-organ failure System Organ Class: 100000167648EUCTR2014-000899-25-EEFaron Pharmaceuticals Ltd152
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmEUCTR2014-000899-25-FIFaron Pharmaceuticals Ltd152
进行中（未招募）
1 期
A study to assess effectiveness and safety of a drug FP-1201-lyo (recombinant human interferon beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic AneurysmEUCTR2014-000899-25-LTFaron Pharmaceuticals Ltd152
进行中（未招募）
不适用
A Phase II Randomised, Double-blind, Parallel Group, 4-week treatment, Adaptive Dose Finding, Multi-centre study evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to three different oral doses of AZD1386 and Placebo in patients with Osteoarthritis of the kneeOsteoarthritis of the kneeMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisMedDRA version: 9.1Level: LLTClassification code 10031165Term: Osteoarthritis kneeEUCTR2008-007797-37-BGAstraZeneca AB520